Corcept Therapeutics | CORT - Debt


Corcept Therapeutics reported $6.11M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Ardelyx USD 207.61M 968K Sep/2025
Assertio Holdings USD 38.87M 615K Sep/2023
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.11M 251K Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
J&J USD 47.93B 2.14B Dec/2025
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Merck USD 49.34B 7.97B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 47B 11.62B Mar/2026
Novartis USD 32.02B 615M Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025
TG Therapeutics USD 253.71M 8.37M Dec/2025